Multidisciplinary Care and Supplemental Therapy in Clear-Cell RCC

EP: 1.Patient Scenario 1: Diagnosis and Risk Stratification of Clear-Cell RCC

EP: 2.Frontline Combination Strategies in Patients With Clear-Cell RCC

EP: 3.Clear-Cell RCC: Impact of Risk Stratification and NCCN Guidelines on 1L Therapy

Now Viewing

EP: 4.Multidisciplinary Care and Supplemental Therapy in Clear-Cell RCC

EP: 5.Patient Scenario 2: Second-Line Treatment Options in Clear-Cell RCC

EP: 6.Clear-Cell RCC: Best Practices in Patient Monitoring

EP: 7.TIVO-3: Tivozanib as Third- or Later-Line Therapy in Clear-Cell RCC

EP: 8.Tivozanib in Clear-Cell RCC: Adverse Event Management Strategies

EP: 9.Tivozanib in Clear-Cell RCC: Dosing Schedule and Adjustments to Therapy

EP: 10.Evolving Treatment Landscape of Clear-Cell Renal Cell Carcinoma

EP: 11.Key Takeaways on the Management of Clear-Cell RCC

EP: 12.Immunotherapy/TKI Combinations Yield Efficacy Benefit in RCC

Summary:

In the context of advanced renal cell carcinoma (RCC) treatment, a patient-centered approach is crucial, considering the overwhelming nature of a cancer diagnosis. The initial clinic visits are focused on understanding the patient’s emotional state, coping mechanisms, and comprehension of their diagnosis. Building a shared understanding between the healthcare team and the patient forms the foundation for informed decision-making.

The multidisciplinary team, comprising oncology nurse navigators, social workers, and pharmacists, plays a pivotal role in managing patients starting systemic therapy for kidney cancer. Emphasis is placed on the collaboration with pharmacists to navigate the complexities of adverse effects, especially when managing overlapping symptoms caused by tyrosine kinase inhibitors (TKIs) and immunotherapies. Addressing issues such as diarrhea, a common adverse effect, involves the expertise of the pharmacy team to differentiate contributing factors and tailor interventions. Supplement use, including herbal and alternative medications, is a common concern for patients seeking relief from cancer-related symptoms or adverse effects. The multidisciplinary approach allows for multiple clinicians to inquire about patient medications, ensuring a comprehensive understanding. Pharmacists engage in separate conversations, providing a dedicated space for patients to discuss alternative treatments. The team considers available data on drug interactions, toxicities, and expected adverse effects of herbal supplements. The cautious approach prioritizes patient safety, presenting data when available and allowing patients to continue certain supplements if deemed safe.

The multidisciplinary team’s collaboration extends to addressing questions about using supplements, recognizing potential drug interactions and liver metabolism issues. In-depth discussions help patients comprehend the totality of their care, fostering a collaborative decision-making process. Beyond medical interventions, the team considers quality of life, highlighting the importance of improving patient outcomes beyond survival metrics. The patient-centered, multidisciplinary approach not only addresses the complexities of advanced RCC treatment but also emphasizes the importance of considering the patient’s values and goals in shaping their care journey.

Summary is AI-generated and reviewed by Cancer Network editorial staff.